WO2000073482A1 - Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders - Google Patents
Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders Download PDFInfo
- Publication number
- WO2000073482A1 WO2000073482A1 PCT/US2000/014582 US0014582W WO0073482A1 WO 2000073482 A1 WO2000073482 A1 WO 2000073482A1 US 0014582 W US0014582 W US 0014582W WO 0073482 A1 WO0073482 A1 WO 0073482A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fiv
- vector
- glucuronidase
- lentiviral vector
- protein
- Prior art date
Links
- 239000013598 vector Substances 0.000 title claims abstract description 144
- 208000015439 Lysosomal storage disease Diseases 0.000 title claims abstract description 26
- 238000001476 gene delivery Methods 0.000 title abstract description 39
- 238000000034 method Methods 0.000 claims abstract description 51
- 210000004556 brain Anatomy 0.000 claims abstract description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 31
- 210000004027 cell Anatomy 0.000 claims description 118
- 108090000623 proteins and genes Proteins 0.000 claims description 87
- 108010060309 Glucuronidase Proteins 0.000 claims description 55
- 102000053187 Glucuronidase Human genes 0.000 claims description 54
- 238000004806 packaging method and process Methods 0.000 claims description 39
- 102000004169 proteins and genes Human genes 0.000 claims description 34
- 230000002950 deficient Effects 0.000 claims description 28
- 239000002245 particle Substances 0.000 claims description 26
- 208000025919 mucopolysaccharidosis type 7 Diseases 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 15
- 230000002207 retinal effect Effects 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 15
- 241000700605 Viruses Species 0.000 claims description 14
- 208000002780 macular degeneration Diseases 0.000 claims description 14
- 230000006820 DNA synthesis Effects 0.000 claims description 11
- 108020004566 Transfer RNA Proteins 0.000 claims description 11
- 201000007737 Retinal degeneration Diseases 0.000 claims description 10
- 230000004258 retinal degeneration Effects 0.000 claims description 10
- 206010056893 Mucopolysaccharidosis VII Diseases 0.000 claims description 9
- 201000001828 Sly syndrome Diseases 0.000 claims description 9
- 102000005327 Palmitoyl protein thioesterase Human genes 0.000 claims description 8
- 108020002591 Palmitoyl protein thioesterase Proteins 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 108060007951 sulfatase Proteins 0.000 claims description 8
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 7
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 6
- 102000005348 Neuraminidase Human genes 0.000 claims description 6
- 108010006232 Neuraminidase Proteins 0.000 claims description 6
- 230000005779 cell damage Effects 0.000 claims description 6
- 208000037887 cell injury Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 6
- 102000040430 polynucleotide Human genes 0.000 claims description 6
- 239000002157 polynucleotide Substances 0.000 claims description 6
- 101000652829 Neosartorya fumigata (strain ATCC MYA-4609 / Af293 / CBS 101355 / FGSC A1100) Exo-alpha-sialidase Proteins 0.000 claims description 5
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 claims description 5
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 claims description 5
- 102000009133 Arylsulfatases Human genes 0.000 claims description 4
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 4
- 102000005262 Sulfatase Human genes 0.000 claims description 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 210000002919 epithelial cell Anatomy 0.000 claims description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 2
- 102100022440 Battenin Human genes 0.000 claims 3
- 101000901683 Homo sapiens Battenin Proteins 0.000 claims 3
- 230000002463 transducing effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 25
- 208000017442 Retinal disease Diseases 0.000 abstract description 14
- 241000713800 Feline immunodeficiency virus Species 0.000 description 87
- 241000699670 Mus sp. Species 0.000 description 59
- 230000014509 gene expression Effects 0.000 description 54
- 210000001508 eye Anatomy 0.000 description 48
- 238000002347 injection Methods 0.000 description 34
- 239000007924 injection Substances 0.000 description 34
- 102000004190 Enzymes Human genes 0.000 description 31
- 108090000790 Enzymes Proteins 0.000 description 31
- 230000000694 effects Effects 0.000 description 29
- 241001465754 Metazoa Species 0.000 description 27
- 210000001519 tissue Anatomy 0.000 description 24
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 23
- 238000012546 transfer Methods 0.000 description 23
- 238000012937 correction Methods 0.000 description 21
- 241001430294 unidentified retrovirus Species 0.000 description 21
- 230000002132 lysosomal effect Effects 0.000 description 20
- 230000013016 learning Effects 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 18
- 108090000765 processed proteins & peptides Proteins 0.000 description 18
- 108010005774 beta-Galactosidase Proteins 0.000 description 17
- 229920001184 polypeptide Polymers 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 16
- 230000001177 retroviral effect Effects 0.000 description 15
- 108091026890 Coding region Proteins 0.000 description 14
- 241000282414 Homo sapiens Species 0.000 description 13
- 238000001415 gene therapy Methods 0.000 description 13
- 150000007523 nucleic acids Chemical class 0.000 description 13
- 238000010361 transduction Methods 0.000 description 13
- 230000026683 transduction Effects 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 108091008695 photoreceptors Proteins 0.000 description 12
- 101000977023 Azospirillum brasilense Uncharacterized 17.8 kDa protein in nodG 5'region Proteins 0.000 description 11
- 101000961984 Bacillus thuringiensis Uncharacterized 30.3 kDa protein Proteins 0.000 description 11
- 101000644901 Drosophila melanogaster Putative 115 kDa protein in type-1 retrotransposable element R1DM Proteins 0.000 description 11
- 101000747702 Enterobacteria phage N4 Uncharacterized protein Gp2 Proteins 0.000 description 11
- 101000758599 Escherichia coli Uncharacterized 14.7 kDa protein Proteins 0.000 description 11
- 101000768930 Lactococcus lactis subsp. cremoris Uncharacterized protein in pepC 5'region Proteins 0.000 description 11
- 101000976302 Leptospira interrogans Uncharacterized protein in sph 3'region Proteins 0.000 description 11
- 101000778886 Leptospira interrogans serogroup Icterohaemorrhagiae serovar Lai (strain 56601) Uncharacterized protein LA_2151 Proteins 0.000 description 11
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 101001121571 Rice tungro bacilliform virus (isolate Philippines) Protein P2 Proteins 0.000 description 11
- 101000818098 Spirochaeta aurantia Uncharacterized protein in trpE 3'region Proteins 0.000 description 11
- 101001026590 Streptomyces cinnamonensis Putative polyketide beta-ketoacyl synthase 2 Proteins 0.000 description 11
- 101000750896 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized protein Synpcc7942_2318 Proteins 0.000 description 11
- 101000916321 Xenopus laevis Transposon TX1 uncharacterized 149 kDa protein Proteins 0.000 description 11
- 101000760088 Zymomonas mobilis subsp. mobilis (strain ATCC 10988 / DSM 424 / LMG 404 / NCIMB 8938 / NRRL B-806 / ZM1) 20.9 kDa protein Proteins 0.000 description 11
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 210000001525 retina Anatomy 0.000 description 11
- 238000003860 storage Methods 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 10
- 102000005936 beta-Galactosidase Human genes 0.000 description 10
- 210000000871 endothelium corneal Anatomy 0.000 description 10
- 210000003712 lysosome Anatomy 0.000 description 10
- 230000001868 lysosomic effect Effects 0.000 description 10
- 125000003729 nucleotide group Chemical class 0.000 description 10
- 239000003981 vehicle Substances 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 230000000750 progressive effect Effects 0.000 description 9
- 230000010076 replication Effects 0.000 description 9
- 108700019146 Transgenes Proteins 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 8
- 210000000981 epithelium Anatomy 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 230000003447 ipsilateral effect Effects 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 210000001577 neostriatum Anatomy 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 201000004569 Blindness Diseases 0.000 description 7
- 210000003169 central nervous system Anatomy 0.000 description 7
- 239000003623 enhancer Substances 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 210000000608 photoreceptor cell Anatomy 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 208000010412 Glaucoma Diseases 0.000 description 6
- 241000713666 Lentivirus Species 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 210000004087 cornea Anatomy 0.000 description 6
- 230000008488 polyadenylation Effects 0.000 description 6
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 6
- 229940081974 saccharin Drugs 0.000 description 6
- 235000019204 saccharin Nutrition 0.000 description 6
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 208000008955 Mucolipidoses Diseases 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000001886 ciliary effect Effects 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- 230000006735 deficit Effects 0.000 description 5
- 230000007850 degeneration Effects 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 108010031345 placental alkaline phosphatase Proteins 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000701161 unidentified adenovirus Species 0.000 description 5
- 229960001600 xylazine Drugs 0.000 description 5
- 241000282324 Felis Species 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 4
- 241000714177 Murine leukemia virus Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108090000820 Rhodopsin Proteins 0.000 description 4
- 230000035508 accumulation Effects 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 108700004025 env Genes Proteins 0.000 description 4
- 239000005090 green fluorescent protein Substances 0.000 description 4
- 229960003299 ketamine Drugs 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 230000007658 neurological function Effects 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 4
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 206010011878 Deafness Diseases 0.000 description 3
- 201000008892 GM1 Gangliosidosis Diseases 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 206010072927 Mucolipidosis type I Diseases 0.000 description 3
- 206010028095 Mucopolysaccharidosis IV Diseases 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 208000012641 Pigmentation disease Diseases 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 102000004330 Rhodopsin Human genes 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 208000000828 Sialic Acid Storage Disease Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 206010064930 age-related macular degeneration Diseases 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000003920 cognitive function Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000002518 glial effect Effects 0.000 description 3
- 208000016354 hearing loss disease Diseases 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000015654 memory Effects 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 208000010978 mucopolysaccharidosis type 4 Diseases 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 108700004029 pol Genes Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000007974 sodium acetate buffer Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 230000031836 visual learning Effects 0.000 description 3
- 208000036443 AIPL1-related retinopathy Diseases 0.000 description 2
- 208000031277 Amaurotic familial idiocy Diseases 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010011777 Cystinosis Diseases 0.000 description 2
- 206010052804 Drug tolerance Diseases 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- 208000017462 Galactosialidosis Diseases 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000006933 Hermanski-Pudlak Syndrome Diseases 0.000 description 2
- 206010071775 Hermansky-Pudlak syndrome Diseases 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 2
- 208000033868 Lysosomal disease Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000713821 Mason-Pfizer monkey virus Species 0.000 description 2
- 208000036626 Mental retardation Diseases 0.000 description 2
- 206010072930 Mucolipidosis type IV Diseases 0.000 description 2
- 102100026502 Mucolipin-1 Human genes 0.000 description 2
- 208000025915 Mucopolysaccharidosis type 6 Diseases 0.000 description 2
- 208000000149 Multiple Sulfatase Deficiency Disease Diseases 0.000 description 2
- 208000035032 Multiple sulfatase deficiency Diseases 0.000 description 2
- 208000008457 Neurologic Manifestations Diseases 0.000 description 2
- 102000010175 Opsin Human genes 0.000 description 2
- 108050001704 Opsin Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 208000013608 Salla disease Diseases 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 201000006754 cone-rod dystrophy Diseases 0.000 description 2
- 210000003683 corneal stroma Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 231100000895 deafness Toxicity 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 210000000959 ear middle Anatomy 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 108700004026 gag Genes Proteins 0.000 description 2
- 101150098622 gag gene Proteins 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 101150118163 h gene Proteins 0.000 description 2
- 230000026781 habituation Effects 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000001744 histochemical effect Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 208000000690 mucopolysaccharidosis VI Diseases 0.000 description 2
- 230000007971 neurological deficit Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 101150088264 pol gene Proteins 0.000 description 2
- 230000001124 posttranscriptional effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 210000003994 retinal ganglion cell Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000005236 sound signal Effects 0.000 description 2
- 230000006886 spatial memory Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000011824 transgenic rat model Methods 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 210000003934 vacuole Anatomy 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- OEANUJAFZLQYOD-CXAZCLJRSA-N (2r,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-5-acetamido-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](OC)O[C@H](CO)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](OC)[C@H](C(O)=O)O1 OEANUJAFZLQYOD-CXAZCLJRSA-N 0.000 description 1
- BFUUJUGQJUTPAF-UHFFFAOYSA-N 2-(3-amino-4-propoxybenzoyl)oxyethyl-diethylazanium;chloride Chemical compound [Cl-].CCCOC1=CC=C(C(=O)OCC[NH+](CC)CC)C=C1N BFUUJUGQJUTPAF-UHFFFAOYSA-N 0.000 description 1
- QRBLKGHRWFGINE-UGWAGOLRSA-N 2-[2-[2-[[2-[[4-[[2-[[6-amino-2-[3-amino-1-[(2,3-diamino-3-oxopropyl)amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2s,3r,4r,5s)-4-carbamoyl-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)- Chemical compound N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(C)=O)NC(=O)C(C)C(O)C(C)NC(=O)C(C(O[C@H]1[C@@]([C@@H](O)[C@H](O)[C@H](CO)O1)(C)O[C@H]1[C@@H]([C@](O)([C@@H](O)C(CO)O1)C(N)=O)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C QRBLKGHRWFGINE-UGWAGOLRSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000029602 Alpha-N-acetylgalactosaminidase deficiency Diseases 0.000 description 1
- 102100034561 Alpha-N-acetylglucosaminidase Human genes 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102100022146 Arylsulfatase A Human genes 0.000 description 1
- 206010068220 Aspartylglucosaminuria Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 241000713826 Avian leukosis virus Species 0.000 description 1
- 201000001321 Bardet-Biedl syndrome Diseases 0.000 description 1
- 102100032487 Beta-mannosidase Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000004201 Ceramidases Human genes 0.000 description 1
- 108090000751 Ceramidases Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 108010036867 Cerebroside-Sulfatase Proteins 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 241000251556 Chordata Species 0.000 description 1
- 208000031879 Chédiak-Higashi syndrome Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 206010012667 Diabetic glaucoma Diseases 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 208000001948 Farber Lipogranulomatosis Diseases 0.000 description 1
- 208000033149 Farber disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 102100028496 Galactocerebrosidase Human genes 0.000 description 1
- 108010042681 Galactosylceramidase Proteins 0.000 description 1
- 241000272496 Galliformes Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 208000009796 Gangliosidoses Diseases 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 1
- 102000004547 Glucosylceramidase Human genes 0.000 description 1
- 108010017544 Glucosylceramidase Proteins 0.000 description 1
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 description 1
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000933465 Homo sapiens Beta-glucuronidase Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 101001010792 Homo sapiens Transcriptional regulator ERG Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 108010053927 Iduronate Sulfatase Proteins 0.000 description 1
- 102000004627 Iduronidase Human genes 0.000 description 1
- 108010003381 Iduronidase Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000032578 Inherited retinal disease Diseases 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000028226 Krabbe disease Diseases 0.000 description 1
- ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 1
- ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 1
- 206010056715 Laurence-Moon-Bardet-Biedl syndrome Diseases 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 208000023147 Lysosomal storage disease with skeletal involvement Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 241000713862 Moloney murine sarcoma virus Species 0.000 description 1
- 206010072928 Mucolipidosis type II Diseases 0.000 description 1
- 206010072929 Mucolipidosis type III Diseases 0.000 description 1
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 description 1
- 101100060131 Mus musculus Cdk5rap2 gene Proteins 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- 108010006140 N-sulfoglucosamine sulfohydrolase Proteins 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 1
- 208000014060 Niemann-Pick disease Diseases 0.000 description 1
- 201000000791 Niemann-Pick disease type B Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 1
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- LTQCLFMNABRKSH-UHFFFAOYSA-N Phleomycin Natural products N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(O)C)NC(=O)C(C)C(O)C(C)NC(=O)C(C(OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C LTQCLFMNABRKSH-UHFFFAOYSA-N 0.000 description 1
- 108010035235 Phleomycins Proteins 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 208000024571 Pick disease Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 206010057430 Retinal injury Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000020221 Short stature Diseases 0.000 description 1
- 208000017460 Sialidosis type 2 Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000713675 Spumavirus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 241000278713 Theora Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- 208000008291 Type B Niemann-Pick Disease Diseases 0.000 description 1
- 108700001567 Type I Schindler Disease Proteins 0.000 description 1
- 208000014769 Usher Syndromes Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 208000026589 Wolman disease Diseases 0.000 description 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 108010030291 alpha-Galactosidase Proteins 0.000 description 1
- 102000005840 alpha-Galactosidase Human genes 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 102000012086 alpha-L-Fucosidase Human genes 0.000 description 1
- 108010061314 alpha-L-Fucosidase Proteins 0.000 description 1
- 108010012864 alpha-Mannosidase Proteins 0.000 description 1
- 102000019199 alpha-Mannosidase Human genes 0.000 description 1
- 108010015684 alpha-N-Acetylgalactosaminidase Proteins 0.000 description 1
- 102000002014 alpha-N-Acetylgalactosaminidase Human genes 0.000 description 1
- 108010009380 alpha-N-acetyl-D-glucosaminidase Proteins 0.000 description 1
- 201000008333 alpha-mannosidosis Diseases 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 206010001902 amaurosis Diseases 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 208000021024 autosomal recessive inheritance Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 108010055059 beta-Mannosidase Proteins 0.000 description 1
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 description 1
- 102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 description 1
- 201000006486 beta-mannosidosis Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000005821 brain abnormality Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000004559 cerebral degeneration Diseases 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 208000006623 congenital stationary night blindness Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000000399 corneal endothelial cell Anatomy 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 229960001815 cyclopentolate Drugs 0.000 description 1
- SKYSRIRYMSLOIN-UHFFFAOYSA-N cyclopentolate Chemical compound C1CCCC1(O)C(C(=O)OCCN(C)C)C1=CC=CC=C1 SKYSRIRYMSLOIN-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- 238000002571 electroretinography Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000003059 ependyma Anatomy 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 101150063836 fin gene Proteins 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007421 fluorometric assay Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 201000008049 fucosidosis Diseases 0.000 description 1
- 201000006440 gangliosidosis Diseases 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000007345 glycogen storage disease Diseases 0.000 description 1
- 201000004502 glycogen storage disease II Diseases 0.000 description 1
- 201000008977 glycoproteinosis Diseases 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 238000007825 histological assay Methods 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000015978 inherited metabolic disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 210000003140 lateral ventricle Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000003458 metachromatic effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000011206 morphological examination Methods 0.000 description 1
- 208000020460 mucolipidosis II alpha/beta Diseases 0.000 description 1
- 208000020468 mucolipidosis III alpha/beta Diseases 0.000 description 1
- 208000005340 mucopolysaccharidosis III Diseases 0.000 description 1
- 208000012251 mucopolysaccharidosis Ih Diseases 0.000 description 1
- 208000011045 mucopolysaccharidosis type 3 Diseases 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000005157 neural retina Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 201000008051 neuronal ceroid lipofuscinosis Diseases 0.000 description 1
- 230000030147 nuclear export Effects 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 230000008397 ocular pathology Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 208000001749 optic atrophy Diseases 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960003733 phenylephrine hydrochloride Drugs 0.000 description 1
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 201000006366 primary open angle glaucoma Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960003981 proparacaine Drugs 0.000 description 1
- 229960001371 proparacaine hydrochloride Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 230000002488 pyknotic effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 208000011985 sialidosis Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000002356 skeleton Anatomy 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 210000003454 tympanic membrane Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
- C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01031—Beta-glucuronidase (3.2.1.31)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- the present invention relates to compositions and methods for treating diseases of the eye, and more specifically, to the use of various gene delivery vectors which direct the expression of selected gene products suitable for treating or preventing diseases of the eye and brain associated with lysosomal storage disorders and other genetic defects.
- MPS Mucopolysaccharidoses
- GAGs glycosaminoglycans
- Patients afflicted with MPS can have a variety of clinical features including short stature, progressive bone and joint abnormalities termed dysostosis multiplex, course facial features, deafness, corneal clouding, hepatosplenomegaly, mental retardation and premature death.
- the lysosomal storage defect can occur in the viscera, brain and skeleton, and the accumulated GAGs have a fibrillogranular appearance ultrastructurally (Vogler et al., J. Inher. Metab. Dis. 21 :575-586, 1998).
- MPS VII hereditary retinal disease caused by ⁇ - glucuronidase deficiency.
- MPS VII hereditary retinal disease caused by ⁇ - glucuronidase deficiency.
- MPS VII it is a progressive condition, with most tissues affected including the CNS.
- Canine and murine models of MPS VII have been described (Haskins et al.,
- Gene therapy has been used to treat a variety of disorders and gene transfer to the eye has been attempted using recombinant vectors such as adenovirus (Li et al., Invest Opthalmol Vis Sci 35:2543-2549, 1994; Borras et al., Gene Ther 6:515-524, 1999; Li and Davidson, PNAS 92:1100-1104, 1995; Sakamoto et al, H Gene Ther
- adeno-associated virus (Ali et al., Hum Gene Ther 9:81-86, 1998, Flannery et al., PNAS 94:6916-6921, 1997; Bennett et al., Invest Opthalmol Vis Sci 38:2857-2863, 1997; Jomary et al., Gene Ther 4:683-690, 1997, Rolling et al., Hum Gene Ther 70:641-648, 1999; Ali et al., Hum Mol Genet 5:591-594, 1996) and human immunodeficiency virus (Miyoshi et al., PNAS 94:10319-23, 1997; Takahashi et al., J Virol 73:7812-7816, 1999).
- adenovirus infects cells only in the anterior segment of the eye, mainly the corneal endothelium and iris pigmented epithelium, while a subretinal injection results mainly in positive RPE and muller cells (Li et al., Invest Opthalmol Vis Sci 35:2543-2549, 1994; Li and Davidson, PNAS 92:1100-1104, 1995; Sakamoto et al., H Gene Ther 5:1088-1097, 1999.
- AAN injected intravitreally results in transduction of the ganglion cell layer and the RPE.
- a subretinal injection produces positive photoreceptors, in addition to the RPE and ganglion cells (Ali et al., Hum Mol Genet 5:591-594, 1996).
- Studies with ⁇ IV injected subretinally have shown efficient transduction of the RPE and photoreceptors (Miyoshi et al., PNAS 94:10319-23, 1997; Takahashi et al., J Virol 73:7812-7816, 1999).
- retroviral gene delivery methods have been extensively utilized in other gene therapy approaches, in part due to: (1) the efficient entry of genetic material (the vector genome) into cells; (2) an active, efficient process of entry into the target cell nucleus; (3) relatively high levels of gene expression; (4) the potential to target particular cellular subtypes through control of the vector-target cell binding and the tissue-specific control of gene expression; (5) a general lack of pre-existing host immunity; (6) substantial knowledge and clinical experience which has been gained with such vectors; and (7) the capacity for stable and long-term expression.
- retroviruses are diploid positive-strand RNA viruses that replicate through an integrated DNA intermediate.
- the retroviral genome Upon infection by the RNA virus, the retroviral genome is reverse-transcribed into DNA by a virally encoded reverse transcriptase that is carried as a protein in each retrovirus.
- the viral DNA is then integrated pseudo-randomly into the host cell genome of the infected cell, forming a "provirus" which is inherited by daughter cells.
- retrovirus the murine leukemia virus, or "MLV”
- MLV murine leukemia virus
- One major disadvantage of MLV-based vectors is that the host range (i.e., cells infected with the vector) is limited, and the frequency of transduction of non-replicating cells is generally low.
- FMV Feline immunodeficiency virus
- the present invention provides compositions and methods for treating and preventing a number of retinal and brain diseases and degenerations such as RP and AMD, using retrovirus-mediated gene transfer and, further, provides other related advantages.
- the present invention provides compositions and methods for treating, preventing, or inhibiting diseases of the eye and the brain, and in particular, diseases of the eye and brain that result from lysosomal storage disease or from deficiency of retinal gene products.
- methods are provided for treating or preventing diseases of the eye or brain comprising the step of intravitreal administration of a gene delivery vector which directs the expression of one or more polypeptides, proteins or enzymes, such that the disease is treated or prevented.
- a viral promoter e.g., CMV
- a tissue-specific promoter e.g., opsin or RPE
- an inducible promoter e.g., tet
- a viral promoter e.g., CMV
- a tissue-specific promoter e.g., opsin or RPE
- an inducible promoter e.g., tet
- Preferred gene delivery vectors suitable for use within the present invention may be generated from retroviruses such as FIV or HIV.
- a wide variety of retinal diseases may be readily treated or prevented, including for example, macular degeneration, diabetic retinopathies, inherited retinal degeneration such as retinitis pigmentosa, glaucoma, retinal detachment or injury and retinopathies.
- Genes encoding a wide variety of polypeptides, proteins or enzymes may be employed, including those which, when expressed, prevent or alleviate the effects of the lysosom
- the invention therefore relates to a method of treating or preventing retinal diseases of the eye, comprising, administering intravitreously a gene delivery vector which directs the expression of a polypeptide, protein or enzyme, such that said retinal disease of the eye is treated or prevented.
- the protein, polypeptide or enzyme is selected from the group consisting of ⁇ -glucuronidase; neuraminidase; sphingomyelinase; sulfatases; arylsulfatase ⁇ ; ⁇ -galactosidase; ⁇ -galactosidase; ceramidase; glucocerebrosidase; ⁇ -hexosaminidase; galactosylceramidase; arylsulfatase A; ⁇ -N- acetylgalactosaminidase; aspartylglycosammidase; ⁇ -L-fucosidase; ⁇ -mannosidase; ⁇ -mannosidase; sialidase; iduronate sulfatase; ⁇ -L-iduronidase; GalNac-4-sulfatase; Gal 6-sulfatase;
- the invention further relates to treating retinal disease of the eye such as macular degeneration; diabetic retinopathy, inherited retinal degeneration, such as retinitis pigmentosa; and glaucoma.
- retinal disease of the eye such as macular degeneration; diabetic retinopathy, inherited retinal degeneration, such as retinitis pigmentosa; and glaucoma.
- the said gene delivery vector is a retrovirus selected from the group consisting of HIV and FIV.
- the invention further provides methods of treating diseases including Sly syndrome; Salla disease; infantile sialic acid storage disease; cystinosis; Morbus Gaucher disease; type 1 sialidosis; Batten's disease; Mucolipidosis Type IV;
- Hermansky-Pudlak syndrome Hermansky-Pudlak syndrome; gangliosidosis; galactosialidosis; Type B Niemann-
- the invention provides a method of treating or preventing cell damage in retinal epithelial cells associated with Sly syndrome in a human comprising administering to the human a gene delivery vector that directs the expression of ⁇ -glucuronidase.
- the gene delivery vector is FIV.
- Figures IA and IB show a comparison of liver sections from a normal (1 A) and MPS Vll-affected (IB) mouse.
- Figures 2 A and 2B show a comparison of brain sections from a normal (2 A) and MPS Vll-affected (2B) mouse.
- Figures 3A-3C show the result of gene transfer to the eye after intravitreous injection of FIV ⁇ gal with evidence of gene transfer to the iris (3 A) and retina (3B and 3C, a higher power view).
- Figure 4 shows that gene transfer with an FIV vector expressing a therapeutic gene product allows for prolonged expression of ⁇ -glucuronidase and extensive activity of ⁇ -glucuronidase throughout the brain.
- Figure 5 shows correction of the pathologic defect in MPS VII mice when a gene is expressed from this FIV vector. There is correction in the region where the virus was injected (5B) and at remote sites (5C). 5A is a control tissue from a normal mouse.
- Gene delivery vehicle refers to a construct which is capable of delivering, and, within preferred embodiments expressing, one or more gene(s) or sequence(s) of interest in a host cell.
- Representative examples of such vehicles include viral vectors, nucleic acid expression vectors, naked DNA, and certain eukaryotic cells (e.g., producer cells).
- lentiviral vector construct refers to a nucleic acid construct derived from a lentivirus which carries, and within certain embodiments, is capable of directing the expression of a nucleic acid molecule of interest.
- Lentiviral vectors can have one or more of the lentiviral wild-type genes deleted in whole or part, as described further below, but retain functional flanking long-terminal repeat (LTR) sequences (also described below). Functional LTR sequences are necessary for the rescue, replication and packaging of the lentiviral virion.
- LTR long-terminal repeat
- a lentiviral vector is defined herein to include at least those sequences required in cis for replication and packaging (e.g., functional LTRs) of the virus.
- the LTRs need not be the wild-type nucleotide sequences, and may be altered, e.g., by the insertion, deletion or substitution of nucleotides, so long as the sequences provide for functional rescue, replication and packaging.
- a lentiviral vector includes at least one transcriptional promoter or promoter/enhancer or locus defining element(s), or other elements that control gene expression by other means such as alternate splicing, RNA export, post-translational modification of messenger, or post-transcriptional modification of protein.
- vector constructs also include a packaging signal, LTRs or functional portions thereof, and positive and negative strand primer binding sites appropriate to the retrovirus used (if these are not already present in the retro viral vector).
- the recombinant lentiviral vector may also include a signal that directs polyadenylation, selectable and/or non-selectable markers, an origin of second strand DNA synthesis, as well as one or more restriction sites and a translation termination sequence.
- markers include, but are not limited to, neomycin (Neo), thymidine kinase (TK), hygromycin, phleomycin, puromycin, histidinol, green fluorescent protein (GFP), human placental alkaline phosphatase (PLAP), DHFR, ⁇ - galactosidase and human growth hormone (hGH).
- such vectors typically include a 5' LTR, a tRNA binding site, a packaging signal, an origin of second strand DNA synthesis, and a 3' LTR or a portion thereof.
- FIV vector are used interchangeably to refer to a lentiviral vector construct, as defined above, which includes one or more FIV sequences.
- such vectors typically include a 5' FIV LTR, a primer binding site, a packaging signal, an origin of second strand DNA synthesis, and a 3' FIV LTR.
- Heterologous sequences that are included in the vector construct are those which encode a protein, such as an enzyme, the expression of which is deficient in the selected target cells.
- “Expression cassette” refers to an assembly which is capable of directing the expression of the sequence(s) or gene(s) of interest.
- the expression cassette includes a promoter or promoter/enhancer which is operably linked to (so as to direct transcription of) the sequence(s) or gene(s) of interest, and often includes a polyadenylation sequence as well.
- the expression cassette described herein may be contained within a plasmid construct.
- the plasmid construct may also include a bacterial origin of replication, one or more selectable markers, a signal which allows the plasmid construct to exist as single-stranded DNA (e.g., a Ml 3 origin of replication), at least one multiple cloning site, and a "mammalian" origin of replication (e.g., a SV40 or adenovirus origin of replication).
- a bacterial origin of replication e.g., a Ml 3 origin of replication
- a signal which allows the plasmid construct to exist as single-stranded DNA e.g., a Ml 3 origin of replication
- at least one multiple cloning site e.g., a "mammalian" origin of replication (e.g., a SV40 or adenovirus origin of replication).
- Packaging cell refers to a cell which contains those elements necessary for production of infectious recombinant retrovirus which are lacking in a recombinant retroviral vector.
- Packaging cells contain one or more expression cassettes which are capable of expressing proteins which encode gag, pol and env-derived proteins.
- Packaging cells can also contain expression cassettes encoding one or more of vif, rev, or ORF 2 in addition to gag/pol and env expression cassettes.
- “Producer cell” and “Vector Producing Cell Line” refer to a cell which contains all elements necessary for production of recombinant vector particles.
- "Lentiviral vector particle” as used herein refers to a recombinant lentivirus which carries at least one gene or nucleotide sequence of interest, which is generally flanked by lentiviral LTRs. The lentivirus may also contain a selectable marker. The recombinant lentivirus is capable of reverse transcribing its genetic material into DNA and incorporating this genetic material into a host cell's DNA upon infection.
- Lentiviral vector particles may have a lentiviral envelope, a non-lentiviral envelope (e.g., an amphotropic or VSV-G envelope), a chimeric envelope or a modified envelope (e.g., truncated envelopes or envelopes containing hybrid sequences).
- a non-lentiviral envelope e.g., an amphotropic or VSV-G envelope
- a chimeric envelope e.g., a chimeric envelope or a modified envelope (e.g., truncated envelopes or envelopes containing hybrid sequences).
- FIV vector particle refers to a lentiviral particle, as defined above, which is derived from FIV.
- transfection is used to refer to the uptake of foreign DNA by a cell.
- a cell has been "transfected" when exogenous DNA has been introduced inside the cell membrane.
- transfection techniques are generally known in the art. See, e.g., Graham et al. (1973) Virology, 52:456, Sambrook et al. (1989) Molecular Cloning, a laboratory manual, Cold Spring Harbor Laboratories, New York, Davis et al. (1986) Basic Methods in Molecular Biology, Elsevier, and Chu et al. Gene 13:197, 1981.
- Such techniques can be used to introduce one or more exogenous DNA moieties, such as a plasmid vector and other nucleic acid molecules, into suitable host cells. The term refers to both stable and transient uptake of the genetic material.
- transduction denotes the delivery of a DNA molecule to a recipient cell either in vivo or in vitro, via a replication-defective viral vector, such as via a recombinant lentiviral vector particle.
- heterologous as it relates to nucleic acid sequences such as gene sequences and control sequences, denotes sequences that are not normally joined together, and/or are not normally associated with a particular cell.
- a “heterologous" region of a nucleic acid construct or a vector is a segment of nucleic acid within or attached to another nucleic acid molecule that is not found in association with the other molecule in nature.
- a heterologous region of a nucleic acid construct could include a coding sequence flanked by sequences not found in association with the coding sequence in nature.
- Another example of a heterologous coding sequence is a construct where the coding sequence itself is not found in nature (e.g., synthetic sequences having codons different from the native gene).
- a cell transformed with a construct which is not normally present in the cell would be considered heterologous for purposes of this invention. Allelic variation or naturally occurring mutational events do not give rise to heterologous DNA, as used herein.
- control elements refers collectively to promoter regions, polyadenylation signals, transcription termination sequences, upstream regulatory domains, origins of replication, internal ribosome entry sites ("IRES"), enhancers, and the like, which collectively provide for the replication, transcription and translation of a coding sequence in a recipient cell. Not all of these control elements need always be present so long as the selected coding sequence is capable of being replicated, transcribed and translated in an appropriate host cell.
- promoter region is used herein in its ordinary sense to refer to a nucleotide region comprising a DNA regulatory sequence, wherein the regulatory sequence is derived from a gene which is capable of binding RNA polymerase and initiating transcription of a downstream (3'-direction) coding sequence.
- operably linked refers to an arrangement of elements wherein the components so described are configured so as to perform their usual function.
- control elements operably linked to a coding sequence are capable of effecting the expression of the coding sequence.
- the control elements need not be contiguous with the coding sequence, so long as they function to direct the expression thereof.
- intervening untranslated yet transcribed sequences can be present between a promoter sequence and the coding sequence and the promoter sequence can still be considered “operably linked" to the coding sequence.
- nucleotide sequences in a particular nucleic acid molecule For the purpose of describing the relative position of nucleotide sequences in a particular nucleic acid molecule throughout the instant application, such as when a particular nucleotide sequence is described as being situated “upstream,” “downstream,” “5,” or “3" relative to another sequence, it is to be understood that it is the position of the sequences in the non-transcribed strand of a DNA molecule that is being referred to as is conventional in the art.
- isolated when referring to a nucleotide sequence, is meant that the indicated molecule is present in the substantial absence of other biological macromolecules of the same type.
- an "isolated nucleic acid molecule which encodes a particular polypeptide" refers to a nucleic acid molecule which is substantially free of other nucleic acid molecules that do not encode the subject polypeptide; however, the molecule may include some additional bases or moieties which do not deleteriously affect the basic characteristics of the composition.
- Homology refers to the percent identity between two polynucleotide or two polypeptide moieties.
- Two DNA, or two polypeptide sequences are "substantially homologous" to each other when the sequences exhibit at least about 50% , preferably at least about 75%, more preferably at least about 80%-85%, preferably at least about 90%, and most preferably at least about 95%-98% sequence identity over a defined length of the molecules.
- substantially homologous also refers to sequences showing complete identity to the specified DNA or polypeptide sequence.
- identity refers to an exact nucleotide-to-nucleotide or amino acid-to-amino acid correspondence of two polynucleotides or polypeptide sequences, respectively. Percent identity can be determined by a direct comparison of the sequence information between two molecules by aligning the sequences, counting the exact number of matches between the two aligned sequences, dividing by the length of the shorter sequence, and multiplying the result by 100. Readily available computer programs can be used to aid in the analysis, such as ALIGN, Dayhoff, M.O. in Atlas of Protein Sequence and Structure M.O. Dayhoff ed., 5 Suppl.
- percent identity of a particular nucleotide sequence to a reference sequence can be determined using the homology algorithm of Smith and Waterman with a default scoring table and a gap penalty of six nucleotide positions.
- Another method of establishing percent identity in the context of the present invention is to use the MPSRCH package of programs copyrighted by the University of Edinburgh, developed by John F. Collins and Shane S. Sturrok, and distributed by IntelliGenetics, Inc. (Mountain View, CA). From this suite of packages the Smith- Waterman algorithm can be employed where default parameters are used for the scoring table (for example, gap open penalty of 12, gap extension penalty of one, and a gap of six).
- BLAST BLAST
- Another alignment program is BLAST, used with default parameters.
- homology can be determined by hybridization of polynucleotides under conditions which form stable duplexes between homologous regions, followed by digestion with single-stranded-specific nuclease(s), and size determination of the digested fragments.
- DNA sequences that are substantially homologous can be identified in a Southern hybridization experiment under, for example, stringent conditions, as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, e.g., Sambrook et al., supra; DNA Cloning, supra; Nucleic Acid Hybridization, supra.
- vertebrate subject any member of the subphylum chordata, including, without limitation, mammals such as cattle, sheep, pigs, goats, horses, and human and non-human primates; domestic animals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs, and the like; birds, including domestic, wild and game birds such as cocks and hens including chickens, turkeys and other gallinaceous birds; and fish.
- mammals such as cattle, sheep, pigs, goats, horses, and human and non-human primates
- domestic animals such as dogs and cats
- laboratory animals including rodents such as mice, rats and guinea pigs, and the like
- birds including domestic, wild and game birds such as cocks and hens including chickens, turkeys and other gallinaceous birds
- fish The term does not denote a particular age. Thus, both adult and newborn animals, as well as fetuses, are intended to be covered.
- the present invention provides compositions and methods for treating, preventing, or, inhibiting retinal diseases of the eye, comprising the general step of administering intravitreously a recombinant FIV vector which directs the expression of one or more polypeptides, proteins or enzymes, such that the retinal disease of the eye is treated or prevented.
- the invention also provides compositions and methods for treating, preventing, or inhibiting diseases of the brain related to lysosomal storage disorders.
- A gene delivery vectors
- B polypeptides, proteins or enzymes for use in treating lysosomal storage diseases
- C methods of administering the gene delivery vectors in the treatment or prevention of retinal diseases of the eye and diseases of the brain.
- retroviral gene delivery vehicles are provided which are constructed to carry or express a selected gene(s) or sequence(s) of interest.
- retroviral gene delivery vehicles of the present invention may be readily constructed from a wide variety of retroviruses, including for example, B, C, and D type retroviruses as well as spumaviruses and lentiviruses such as FIV, HIV, HIV-1 , HIV-2 and SIV (see RNA Tumor Viruses, Second Edition, Cold Spring Harbor Laboratory, 1985).
- retroviruses may be readily obtained from depositories or collections such as the American Type Culture Collection ("ATCC”; 10801 University Boulevard., Manassas, VA 20110-2209), or isolated from known sources using commonly available techniques. Any of the above retroviruses may be readily utilized in order to assemble or construct retroviral gene delivery vehicles given the disclosure provided herein, and standard recombinant techniques (e.g., Sambrook et al, Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press, 1989; Kunkle, PNAS 52:488, 1985). In addition, within certain embodiments of the invention, portions of the retroviral gene delivery vehicles may be derived from different retroviruses.
- retrovector LTRs may be derived from a Murine Sarcoma Virus, a tRNA binding site from a Rous Sarcoma Virus, a packaging signal from a Murine Leukemia Virus, and an origin of second strand synthesis from an Avian Leukosis Virus.
- retrovector constructs comprising a 5' LTR, a tRNA binding site, a packaging signal, one or more heterologous sequences, an origin of second strand DNA synthesis and a 3' LTR, wherein the vector construct lacks gaglpol or env coding sequences.
- retrovirus vectors are provided wherein viral promoters, preferably CMV or SV40 promoters and/or enhancers are utilized to drive expression of one or more genes of interest.
- viral promoters preferably CMV or SV40 promoters and/or enhancers are utilized to drive expression of one or more genes of interest.
- retrovirus vectors are provided wherein tissue-specific promoters are utilized to drive expression of one or more genes of interest.
- Retrovirus vector constructs for use with the subject invention may be generated such that more than one gene of interest is expressed. This may be accomplished through the use of di- or oligo-cistronic cassettes (e.g., where the coding regions are separated by 120 nucleotides or less, see generally Levin et al., Gene 705:167-174, 1991), or through the use of Internal Ribosome Entry Sites ("IRES").
- IRS Internal Ribosome Entry Sites
- self-inactivating (SIN) vectors are made by deleting promoter and enhancer elements in the U3 region of the 3 'LTR, including the TATA box and binding sites for one or more transcription factors. The deletion is transferred to the 5 'LTR after reverse transcription and integration in transduced cells.
- FIV vectors are particularly preferred for use herein. FIV vectors may be readily constructed from a wide variety of FIV strains.
- FIV strains and molecular clones of such isolates include the Petaluma strain and its molecular clones FIV34TF10 and FIV 14 (Olmsted et al., PNAS 5(5:8088-8092, 1989; Olmsted et al., PNAS 56:2448-2452, 1989; Talbot et al., PNAS 56:5743-5747, 1989), the San Diego strain and its molecular clone PPR (Phillips et al., J. Virology 64:4605- 4613, 1990), the Japanese strains and their molecular clones FTM191CG and FIV- TM2 (Miyazawa et al., J.
- FIV strains may either be obtained from feline isolates, or more preferably, from depositories or collections such as the ATCC, or isolated from known sources using commonly available techniques. Any of the above FIV strains may be readily utilized in order to assemble or construct FIV gene delivery vehicles given the disclosure provided herein, and standard recombinant techniques (e.g., Sambrook et al, Molecular Cloning: A laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, 1989; Kunkle, PNAS 52:488, 1985; International Publication Nos.
- portions of the FIN gene delivery vehicles may be derived from different viruses.
- recombinant FIV vector or LTR sequences may be partially derived or obtained from HIV, a packaging signal from SIV, and an origin of second strand synthesis from HIV-2.
- FIV vector constructs are provided comprising a 5' FIV LTR, a tR ⁇ A binding site, a packaging signal, one or more heterologous sequences, an origin of second strand D ⁇ A synthesis, an R ⁇ A export element and a 3' FIV LTR.
- LTRs Long Terminal Repeats
- U5, R and U3 These elements contain a variety of signals which are responsible for the biological activity of a retrovirus, including for example, promoter and enhancer elements which are located within U3. LTRs may be readily identified in the provirus (integrated D ⁇ A form) due to their precise duplication at either end of the genome.
- a 5' FIV LTR should be understood to include as much of the native 5' FIV LTR in order to function as a 5' promoter or promoter/enhancer element to allow reverse transcription and integration of the D ⁇ A form of the vector.
- the 3' FIV LTR should be understood to include as much of the 3' FIV LTR to function as a polyadenylation signal to allow reverse transcription and integration of the D ⁇ A form of the vector.
- FIV vector constructs may contain hybrid FIV LTRs where up to 75% of the wildtype FIV LTR sequence is deleted and replaced by one or more viral or non-viral promoter or promoter/enhancer elements (e.g., other retroviral LTRs and/or non-retroviral promoters or promoter/enhancers such as the CMV promoter/enhancer or the SV40 promoter) similar to the hybrid LTRs described by Chang, et al., J. Virology 67, 743-752, 1993; Finer, et al., Blood 83, 43-50, 1994 and Robinson, et al., Gene Therapy 2, 269-278, 1995.
- viral or non-viral promoter or promoter/enhancer elements e.g., other retroviral LTRs and/or non-retroviral promoters or promoter/enhancers such as the CMV promoter/enhancer or the SV40 promoter
- tRNA binding site and origin of second strand DNA synthesis are also important for a retrovirus to be biologically active, and may be readily identified by one of skill in the art.
- tRNA binds to a retroviral tRNA binding site by Watson-Crick base pairing, and is carried with the retrovirus genome into a viral particle.
- the tRNA is then utilized as a primer for DNA synthesis by reverse transcriptase.
- the tRNA binding site may be readily identified based upon its location just downstream from the 5' LTR.
- DNA synthesis is, as its name implies, important for the second strand DNA synthesis of a retrovirus. This region, which is also referred to as the poly-purine tract, is located just upstream of the 3' LTR.
- the packaging signal sequence of FIV directs packaging of viral genetic material into the viral particle.
- a major part of the packaging signal in FIV lies between the 5' FIV LTR and the gag/pol sequence with the packaging signal likely overlapping in part with the 5' area of the gag/pol sequence.
- certain preferred recombinant FIV vector constructs for use herein also comprise one or more genes of interest, each of which is discussed in more detail below.
- the FIV vectors may, but need not, include an RNA export element (also variously referred to as RNA transport, nuclear transport or nuclear export elements) which may be the FIV RRE (Rev- responsive element) or a heterologous transport element.
- RNA export elements include the Mason-Pfizer monkey virus constitutive transport element, the MPMV CTE (Bray et al., PNAS USA 91, 1256- 1260, 1994), the Hepatitis B Virus posttranscriptional regulatory element, the HBV PRE (Huang et al., Mol. Cell. Biol. 73:7476-7486, 1993 and Huang et al., J. Virology 65:3193-3199, 1994), other lentiviral Rev-responsive elements (Daly et al., Nature 342:816-819, 1989 and Zapp et al., Nature 342:714-716, 1989) or the PRE element from the woodchuck hepatitis virus.
- the Mason-Pfizer monkey virus constitutive transport element the MPMV CTE (Bray et al., PNAS USA 91, 1256- 1260, 1994)
- the Hepatitis B Virus posttranscriptional regulatory element the HBV PRE (Huang et al., Mol. Cell. Biol
- RNA export elements include the element in Rous sarcoma virus (Ogert et al., J. Virology 70:3834-3843, 1996; Liu & Mertz, Genes & Dev. 9:1766-1789, 1995) and the element in the genome of simian retrovirus type 1 (Zolotukhin et al., J. Virology 65:7944-7952, 1994).
- Other potential elements include the elements in the histone gene (Kedes, Annu. Rev. Biochem.
- FIV vector constructs which lack both gag/pol and env coding sequences may be used with the present invention.
- the phrase "lacks gag/pol or env coding sequences" should be understood to mean that the FIV vector contains less than 20, preferably less than 15, more preferably less than 10, and most preferably less than 8 consecutive nucleotides which are found in gag/pol or env genes, and in particular, within gag/pol or env expression cassettes that are used to construct packaging cell lines for the FIV vector construct.
- This aspect of the invention provides for FIV vectors having a low probability of undesirable recombination with gag/pol or env sequences which may occur in a host cell or be introduced therein, for example, by transformation with an expression cassette.
- FIV vector constructs lacking gag/pol or env sequences may be accomplished by partially eliminating the packaging signal and/or the use of a modified or heterologous packaging signal.
- FIV vector constructs are provided wherein a portion of the packaging signal that may extend into, or overlap with, the FIV gag/pol sequence is modified (e.g., deleted, truncated or bases exchanged).
- FIV vector constructs are provided which include the packaging signal that may extend beyond the start of the gag/pol gene.
- the packaging signal that may extend beyond the start of the gag/pol gene is modified in order to contain one, two or more stop codons within the gag/pol reading frame. Most preferably, one of the stop codons eliminates the gag/pol start site.
- the introduced mutation may cause a frame shift in the gag/pol coding region.
- retroviral gene delivery vehicles may likewise be utilized within the context of the present invention, including for example those described in EP
- Packaging cell lines suitable for use with the above described retrovector constructs may be readily prepared (see, e.g., U.S. Patent Nos. 5,591,624 and 6,013,517; and International Publication No. WO 95/30763), and utilized to create producer cell lines (also termed vector cell lines or "VCLs") for the production of recombinant vector particles.
- producer cell lines also termed vector cell lines or "VCLs"
- the parent cell line from which the packaging cell line is derived can be selected from a wide variety of mammalian cell lines, including for example, human cells, monkey cells, feline cells, dog cells, mouse cells, and the like.
- potential packaging cell line candidates are screened by isolating the human placental alkaline phosphatase (PLAP) gene from the N2-derived retroviral vector pB AAP, and inserting the gene into the FIV vector construct.
- the construct is co-transfected with a VSV-G encoding expression cassette (e.g., pMLP-G as described by Emi et al., J. Virology 65, 1202-1207, 1991; or pCMV-G, see US Patent No. 5,670,354) into 293T cells, and the virus harvested 48 hours after transfection.
- the resulting virus can be utilized to infect candidate host cells which are subsequently FACS-analyzed using antibodies specific for PLAP.
- Candidate host cells include, e.g., human cells such as HeLa (ATCC CCL 2.1), HT- 1080 (ATCC CCL 121), 293 (ATCC CRL 1573), Jurkat (ATCC TIB 153), supTl (NIH AIDS Research and Reference reagent program catalog #100), and CEM (ATCC CCL 119) or feline cells such as CrFK (ATCC CCL 94), G355-5 (Ellen et al., Virology 757:165-177, 1992), MYA-1 (Dahl et al., J. Virology 67:1602-1608, 1987) or 3201-B (Ellen et al., Virology 757:165-177, 1992). Production of p24 and reverse transcriptase can also be analyzed in the assessment of suitable packaging cell lines.
- human cells such as HeLa (ATCC CCL 2.1), HT- 1080 (ATCC CCL 121), 293 (ATCC CRL 15
- packaging expression cassettes may encode either gag/pol sequences alone, gag/pol sequences and one or more of vif, rev or ORF 2, or one or more of vif, rev or ORF 2 alone and may contain an RNA export element.
- packaging cell line may contain only ORF 2, vif or rev alone, ORF 2 and vif ORF 2 and rev, vif and rev or all three of ORF 2, vif an ⁇ rev.
- Packaging cell lines may also comprise a promoter and a sequence encoding
- ORF 2, vif, rev, or an envelope e.g., VSV-G
- the promoter is operably linked to the sequence encoding ORF 2, vif rev, or the envelope.
- envelope e.g., VSV-G
- additional expression cassettes facilitating the transactivation of the inducible promoter may be incorporated.
- the expression cassette may or may not be stably integrated.
- the packaging cell line upon introduction of an FIV vector, may produce particles at a concentration of greater than 10 3 , IO 4 , 10 5 ,10 6 , IO 7 , 10 8 , or, IO 9 cfu ml.
- FIV-based vectors In humans, there are numerous inherited metabolic diseases affecting the CNS, many of which are the result of a deficiency in a soluble lysosomal enzyme, which would benefit from FIV-based gene therapy as disclosed herein.
- the long-lasting expression conferred by FIV-based vectors could be improved further if coupled to recent advancements made in transcriptional regulation of transgene expression.
- Such vectors may find application not only to correction of lysosomal storage disease in humans, but also to diseases which may benefit from the protective effects of secreted growth factors, such as Parkinson's disease, Alzheimers disease, and the dominant neurodegenerative diseases such as Huntington's and the spinal cerebellar ataxias.
- Lysosomal diseases in humans that are amenable to treatment using the methods of the invention include Batten's disease (neuronal ceroid lipofuscinosis), which has autosomal recessive inheritance (Marshman et al., Aust. N. Z. J. Ophthalmol. (1998) 26:251-254); mucolipidosis type IV, characterized by retinal degeneration and brain abnormalities (Frei et al. (1998) Neurology 51:565-569; Siegel et al. (1998) Elec. Clin. Neurophys. 106:400-403); and infantile cystinosis (Broyer, M. (1997) Rev. Prat. 47:1550-1553).
- Hermansky-Pudlak syndrome which is an often fatal autosomal recessive disorder (Feng et al. (1997) Hum. Mol. Genet. 6:793-797), is also suitable for treatment according to the invention.
- Feng et al. describe a mouse disease that is homologous to the human syndrome and provides an animal model for the human disease, as well as for the Chediak-Higashi syndrome. Both human syndromes are characterized by lysosomal storage defects, and HPS is a single-gene disorder.
- Oh et al. in Nat. Genet. 14:300-306 (1996) describe a transmembrane protein that is defective in HPS patients due to truncation caused by a frameshift mutation.
- Suitable diseases include adult form galactosialidosis (Usui et al. (1993) Metab. Pediatr. Syst. Ophthalmol. 16:19-22); Salla disease (Mancini et al. (1992) Eur. J. Pediatr. 151:590-595); Type B Niemann-Pick disease resulting from deficiency or decreased activity of sphingomyelinase (Barton et al. (1992) Metab. Pediatr. Syst. Ophthalmol. 15:16-20); multiple sulfatase deficiency, or Austin's disease (al Aqeel et al. (1992) J. Child Neurol. 7 Suppl.
- Morquio syndrome systemic mucopolysaccharidosis IV A which can exhibit inclusions distributed in various parts of the eye including the retinal pigment epithelium (Iwamoto et al. (1990) Graefes Arch. Clin. Exp. Ophthalmol. 228:342-349); and ⁇ -galactosidase deficiency (Andia et al. (1978) Clin. Genet. 14:16-23).
- the methods of the invention also have use in the veterinary field including treatment of domestic pets and farm animals.
- Murnane at al. (1994) described an ovine form of GM-1 gangliosidosis, and detected CNS abnormalities and blindness in some animals (J. Vet. Intern. Med. 8:221-223. Deficiencies of ⁇ -galactosidase and ⁇ - neuraminidase have also been reported in sheep (Murnane et al. (1989) Am. J. Pathol. 134:263-270), with CNS and ocular involvement. Stramm et al. ((1986) Invest. Ophthamol. Vis. Sci.
- the present invention provides methods which generally comprise the step of intravitreously administering a gene delivery vector which directs the expression of one or more proteins, polypeptides or enzymes to the retina in order to treat, prevent, or inhibit the progression of a retinal disease.
- the present invention provides methods for administering a gene delivery vehicle to the brain, wherein the expression of one or more polypeptides, proteins, or enzymes is directed.
- the terms "treated, prevented, or, inhibited” refer to the alteration of a disease course or progress in a statistically significant manner.
- Determination of whether a disease course has been altered may be readily assessed in a variety of model systems, discussed in more detail below, which analyze the ability of a gene delivery vector to delay, prevent or rescue photoreceptors, as well as other retinal cells, from cell death, or to delay or prevent cell damage or death in the brain.
- a wide variety of retinal diseases may be treated given the teachings provided herein.
- gene delivery vectors are administered to a patient intravitreously in order to treat or prevent macular degeneration.
- macular degeneration the leading cause of visual loss in the elderly is macular degeneration (MD), which has an increasingly important social and economic impact in the United States.
- AMD age related macular degeneration
- laser treatment has been shown to reduce the risk of extensive macular scarring from the "wet" or neovascular form of the disease, there are currently no effective treatments for the vast majority of patients with MD.
- gene delivery vectors can be administered to a patient intravitreously in order to treat or prevent diabetic retinopathy, or other vascular diseases of the retina.
- gene delivery vectors can be administered to a patient intravitreously in order to treat or prevent an inherited retinal degeneration.
- a patient intravitreously is administered to a patient intravitreously in order to treat or prevent an inherited retinal degeneration.
- RP retinitis pigmentosa
- photoreceptor cells and the RPE.
- Sly syndrome Other inherited conditions include Sly syndrome; Bardet-Biedl syndrome (autosomal recessive); Congenital amaurosis (autosomal recessive); Cone or cone-rod dystrophy (autosomal dominant and X-linked forms); Congenital stationary night blindness (autosomal dominant, autosomal recessive and X-linked forms); Macular degeneration (autosomal dominant and autosomal recessive forms); Optic atrophy, autosomal dominant and X-linked forms); Retinitis pigmentosa (autosomal dominant, autosomal recessive and X-linked forms); Syndromic or systemic retinopathy (autosomal dominant, autosomal recessive and X-linked forms); and Usher syndrome (autosomal recessive).
- This group of debilitating conditions affects approximately 100,000 people in the United States alone.
- gene delivery vectors can be administered to a patient intravitreously in order to treat or prevent glaucoma.
- Glaucoma is a heterogeneous group of disorders that share a distinct type of optic nerve damage that leads to loss of visual function. The disease is manifest as a progressive optic neuropathy that, if left untreated, leads to blindness. It is estimated that as many as 3 million Americans have glaucoma and, of these, as many as 120,000 are blind as a result. Furthermore, it is the number one cause of blindness in African- Americans. Its most prevalent form, primary open-angle glaucoma, can be insidious. This form usually begins in midlife and progresses slowly but relentlessly. If detected early, disease progression can frequently be arrested or slowed with medical and surgical treatment.
- mice In the brain, both neurons and cells of glial lineage are affected.
- the brain lysosomal storage and decreased neuronal numbers may contribute to the behavioral, memory, and cognitive deficits seem in MPS VII mice (Chang et al., Neuro Report 4:507-510, 1993).
- clinical features related to brain lysosomal storage include deafness and mental retardation.
- the morphological aspects of hearing loss in affected mice include thickening of the tympanic membrane, otitis media with expansion of the middle ear mucos, deformation of the middle ear ossicles, and inner ear alterations (Berry et al, Lab. Invest. 77:438-445, 1994).
- Gene delivery vectors are delivered to the eye by intravitreous injection.
- the vitreous is approached either through the ora serata or directly through the pupil, negotiating the needle around the lens.
- the primary target cells to be transduced are the retinal ganglion cells, which are the retinal cells primarily affected in glaucoma.
- the injection volume of the gene delivery vector can large, as the volume is not constrained by the anatomy of the interphotoreceptor or subretinal space. Acceptable dosages in this instance can range from 25 ⁇ l to 1000 ⁇ l.
- the retinal pigment epithelium (RPE) cells are the target cells. Both cell types are targeted by the FIV virus.
- Gene delivery vectors are delivered to the brain of mice by injection into the straitum or right lateral ventricle. Intraventricular injection results in transduction of both ependyma and choroidal epithelium.
- assays may be utilized in order to determine appropriate dosages for administration, or to assess the ability of a gene delivery vector to treat or prevent a particular disease. Certain of these assays are discussed in more detail below.
- Electroretinographic analysis can be utilized to assess the effect of gene delivery administration into the retina. Briefly, animals are dark adapted overnight and then in dim red light, then anesthetized with intramuscular injections of xylazine (13 mg/kg) and ketamine (87 mg/kg). Full-field scotopic ERGs are elicited with 10- ⁇ sec flashes of white light and responses were recorded using a UTAS-E 2000 Visual Electrodiagnostic System (LKC Technologies, Inc., Gaithersburg, MD).
- the corneas of the rats are anesthetized with a drop of 0.5% proparacaine hydrochloride, and the pupils dilated with 1% atropine and 2.5% phenylephrine hydrochloride.
- Small contact lenses with gold wire loops are placed on both corneas with a drop of 2.5% methylcellulose to maintain corneal hydration.
- a silver wire reference electrode is placed subcutaneously between the eyes and a ground electrode is placed subcutaneously in the hind leg. Stimuli are presented at intensities of -1.1, 0.9 and 1.9 log cd m ⁇ 2 at 10-second, 30-second and 1 -minute intervals, respectively.
- Responses are amplified at a gain of 4,000, filtered between 0.3 to 500 Hz and digitized at a rate of 2,000 Hz on 2 channels. Three responses are averaged at each intensity.
- the a- waves are measured from the baseline to the peak in the cornea-negative direction, and b-waves are measured from the cornea-negative peak to the major cornea-positive peak.
- the values from all the stimulus intensities are averaged for a given animal.
- Retinal tissue analysis can also be utilized to assess the effect of gene delivery administration into the retina. This procedure is described in more detail below in Example 2.
- mice neurological function can be measured by EEG. Behavioral, memory, and cognitive function can be assayed as described. (Chang et al., Neuro Report 4:507-510, 1993.)
- Tissues can be harvested from treated mice or primates, and processed for evaluation of lysosomal distension using routine procedures. In this invention it is useful to evaluate, for example, the ipsilateral striatum, ipsilateral cortex, and contra- lateral cortex. Measurements performed over time can indicate increasing correction of cells distant to the vector administration site. CSF can also be collected and evaluated for protein levels or enzyme activity, particularly if the vector encodes a secretable enzyme. 5.
- Gene delivery vectors may be prepared as a pharmaceutical product suitable for direct administration.
- the vector should be admixed with a pharmaceutically acceptable carrier for intravitreous administration.
- suitable carriers are saline or phosphate buffered saline.
- EXAMPLE 1 ⁇ -GLUCURONIDASE EXPRESSION IN NEURONAL TISSUE OF MPS VII MICE ⁇ -glucuronidase deficiency, or MPS VII, is representative of a group of lysosomal storage disorders in humans characterized by accumulations of proteoglycans. The disease is progressive, with most tissues affected including the CNS. Mouse models for ⁇ -glucuronidase deficiency reflect characteristics of the human disorder, and cells in diseased tissues contain numerous, distended lysosomes. In the brain, both neurons and cells of glial lineage are affected. Figure 1 illustrates the VII mice (IB) compared to normal liver (1 A).
- Figure 2 illustrates lysosomal granules in brain of MPS VII mice (2B) compared to normal brain (2A).
- FIV ⁇ gluc vector-mediated gene transfer resulted in robust levels of expression in the injected hemisphere, 3 weeks after injection of vector.
- a representative coronal section from a mouse sacrificed 3 weeks after injection is shown in Figure 4. The level of activity did not decline by 18 weeks, and there was no evidence of inflammatory infiltrate.
- RNA analysis for human ⁇ -glucuronidase mRNA confirmed that transduction was limited to cells near the injection site, and suggests that mRNA and/or virus was not transported to distant cells. Thus, the extensive distribution of enzyme likely results from secretion by transduced cells, followed by distribution via the CSF and extracellular fluids, with uptake by distant cells.
- Tissues harvested from ⁇ -glucuronidase deficient mice injected into the right striatum with FIV ⁇ gluc vector were also processed for evaluation of lysosomal distension.
- tissues from mice sacrificed 3 weeks after gene transfer correction was noted in the ipsilateral striatum, ipsilateral cortex, and modest reductions in storage product were noted in the contralateral cortex.
- This extensive correction was maintained at 18 weeks the last time point studied because of the shortened life spans of these animals (approximately 6 months). The results suggest that persistent expression of this enzyme, approximately 2-5% of which is secreted, can result in correction of cells at increasing distances over time.
- FIV-based vectors devoid of accessory proteins, can globally correct a severe neurologic deficit in the brains of mice suffering from lysosomal storage disease.
- FIV vectors for use in this example were generated essentially as described in International Publication No. WO 99/36511 , published July 22, 1999. Specifically, FIV packaging constructs were generated in a series of steps from the full-length FIV molecular clone, FIV-34TF10 (NIH AIDS Research and Reference Reagent Program, Cat. No. 1236; Phillips et al, J. Virol.
- the FIV vector construct pVET L C ⁇ gal (pVET L C ⁇ in ref (Johnston et al., J Virol 73:4991-5000, 1999), was generated by inserting an expression cassette consisting of the CMV promoter followed by the ⁇ -galactosidase gene into the pVET L FIV vector backbone.
- the pVET L backbone contains the FIV 5' LTR, in which the FIV U3 region is replaced by the CMV promoter/enhancer, 0.5 kb of Gag coding region, a multicloning site and the FIV 3' LTR (Johnston et al., J Virol 73:4991-5000, 1999).
- FIV 5' LTR in which the FIV U3 region is replaced by the CMV promoter/enhancer, 0.5 kb of Gag coding region, a multicloning site and the FIV 3' LTR
- the ⁇ -glucuronidase cDNA was liberated from pAdRSV4 by digestion with Xho I and the resulting fragment ligated into Sal I digested/CIP treated pVET L RSV to generate pVET L Rgluc (+polyA).
- a portion of the ⁇ - glucuronidase cDNA was amplified by PCR and the product digested with Bgl II and Xho I in order to remove the polyadenylation signal from the cDNA.
- pVET L Rgluc To generate pVET L Rgluc, the resulting fragment was joined in a three-way ligation with an Nco II Bgl II fragment and a Xho l/Nco I fragment from pVET L Rgluc (+poly A). All constructs were screened by restriction enzyme digestion and the sequence of regions amplified by PCR confirmed by sequence analysis. Oligonucleotides were synthesized by Operon Technologies, Inc.(Alameda, CA) and sequences as well as more detailed cloning methods are available upon request. Construction of the VSV- G envelope expression plasmid, pCMV-G, has been described (Yee et. al., PNAS 91 :9564, 1994).
- Pseudotyped FIV ⁇ gluc and FIV ⁇ gal vector particles were generated by transient transfection of plasmid DNA into 293T cells plated one day prior to transfection at a density of 2.8 x IO 6 cells per 10 cm diameter culture dish. Cotransfections were performed using a 1 :2:1 molar ratio of FIV packaging construct, FIV vector construct and VSV-G envelope-expressing plasmid. DNA complexes were prepared using calcium phosphate (Profectin kit; Promega Corp. Madison, WI) and transfected into cells according to the manufacturer's instructions. The medium was replaced 8-16 hr after transfection and the supernatant harvested twice between 32 and 48 hr after the start of transfection.
- the harvested supernatants were filtered through a 0.45 M Nalgene filter and stored at -70 °C or concentrated prior to storage. Supernatants were concentrated by centrifugation (Johnston et al., J Virol 73:4991- 5000). Vector titers were determined on HT1080 cells by serial dilution and assay for ⁇ -galactosidase or ⁇ -glucuronidase expression (Li et al., PNAS 92:7700-7704, 1995). C57BL/6 mice were obtained from Harlan Sprague (Indianapolis, IN). These mice are deficient in ⁇ -glucuronidase and provide an accepted animal model for the study of lysosomal storage disease.
- mice with a deficiency in this soluble lysosomal enzyme manifest both visceral and CNS manifestations, thus recapitulating the human syndrome, also known as Sly syndrome or MPS NIL
- Sly syndrome also known as Sly syndrome or MPS NIL
- the inability to appropriately degrade proteoglycans leads to progressive accumulation of precursor products in the lysosomes.
- enzyme production and release by a subpopulation of parenchymal cells within the brain results in widespread clearing of metabolic precursors.
- the ⁇ -glucuronidase-deficient mice were anesthetized with ketamine/xylazine (ketamine 100-125 mg/kg, xylazine 10-12.5 mg/Kg).
- mice were injected unilaterally with 5 ⁇ l
- mice were first deprived of water for 12-16 hours and habituated to a saccharin solution before being introduced into the RAPC for the first time.
- a 0.2% solution of saccharin dissolved in water was provided for 30 minutes twice a day for 2 days, after which regular drinking water was provided ad libitum.
- mice were given four apparatus habituation sessions, each allowed to freely explore the chambers and consume saccharin drops: 1) Placed in front and in back of all doors with all doors taped open (session A); 2) in front and in back of all doors with all doors unlatched (session B); 3) only in back of C and D doors with all doors unlatched (session C); 4) only in back of D doors with all doors unlatched (session D).
- mice were tested over the course of four experimental sessions (sessions l A and 3/4 were separated by 5 weeks).
- a 12 hour water deprivation period preceded all behavioral test sessions, which occurred approximately every third day, with ad libitum water on non-test days for the remainder of the study.
- Each session consisted of three presentations each of the repeated acquisition (RA) component and the performance (P) component.
- RA repeated acquisition
- P performance
- the specific door sequence changed unpredictably with each successive test session (not trial) according to a matrix that prevented the same door on a given panel from being open on consecutive sessions.
- the P component the sequence of doors leading to saccharin was constant across sessions.
- a static audio signal was played for the duration of the P component as a discriminative stimulus signaling that component, whereas the absence of the audio signal served as the discriminative stimulus for the RA component.
- a total of three trials were carried out during each presentation of the RA and P components during a session, for a total of 18 trials per session.
- Latency was measured as the time required for a subject to leave the start box, successfully navigate through the four compartments, and consume the saccharin solution in the goal box. Mice were manually placed in the goal box in the event of failure to reach it within 10 minutes on any trial. In addition to latency, the number and sequence of door errors made by the subject were also recorded.
- numbers of errors in the performance component of the +/- group ranged from 10 to 16 with values of the -/- group higher at 24 to 29.
- Latencies and error number in the RAPC learning component increased in ⁇ -glucuronidase deficient mice tested between the 8th and 13th week of age indicating progressive impairment of cognitive function.
- -/- mice actually exhibited significantly shorter latencies during the first session, but these subsequently increased, such that by sessions 3 and 4, latencies of the -/- group were significantly higher than those of the +/- group (approximately 165 vs. 120 sec).
- latency values of the -/- group were also significantly shorter during the first 2 sessions in the performance component of the schedule (approximately 25 vs.
- FIV ⁇ gluc ⁇ vif ⁇ orf2 gene transfer had a profound positive impact on the progressive neurodegenerative disease in the ⁇ - glucuronidase deficient mouse model.
- the RAPC data indicate that gene transfer restored cognitive function to brains of ⁇ -glucuronidase deficient mice.
- FIV-based vectors devoid of accessory proteins, can reverse a severe neurologic deficit in the brains of mice with an established lysosomal storage disease.
- TRANSGENIC RAT S334TER AS A MODEL FOR PHOTORECEPTOR DEGENERATION
- rhodopsin is a seven-transmembrane protein found in photoreceptor outer segments, which acts as a photopigment.
- the S334ter mutation results in the truncation of the C-terminal 15 amino acid residues of rhodopsin and is similar to rhodopsin mutations found in a subset of patients with retinitis pigmentosa (RP).
- RP retinitis pigmentosa
- RP is a heterogeneous group of inherited retinal disorders in which individuals experience varying rates of vision loss due to photoreceptor degeneration.
- photoreceptor cell death progresses to blindness.
- Transgenic S334ter rats are born with normal number of photoreceptors.
- the mutant rhodopsin gene begins expression at postnatal day 5 in the rat, and photoreceptor cell death begins at postnatal day 10-15.
- transgenic line S334ter-3 approximately 70% of the outer nuclear layer has degenerated by day 60 in the absence of any therapeutic intervention.
- the retinal degeneration in this model is consistent from animal to animal and follows a predictable and reproducible rate. This provides an assay for therapeutic effect by morphological examination of the thickness of the photoreceptor nuclear layer and comparison of the treated eye to the untreated (contralateral) eye in the same individual animal.
- the rats are euthanized by overdose of carbon dioxide inhalation and immediately perfused intracardially with a mixture of mixed aldehydes (2% formaldehyde and 2.5% glutaraldehyde). Eyes are removed and embedded in epoxy resin, and 1 ⁇ m thick histological sections are made along the vertical meridian. Tissue sections are aligned so that the ROS and Muller cell processes crossing the inner plexiform layer are continuous throughout the plane of section to assure that the sections are not oblique, and the thickness of the ONL and lengths of RIS and ROS are measured. These retinal thickness measurements are plotted and establish the baseline retinal degeneration rates for the animal model. The assessment of retinal thickness is as follows: briefly, 54 measurements of each layer or structure are made at set points around the entire retinal section. These data are either averaged to provide a single value for the retina, or plotted as a distribution of thickness or length across the retina.
- TgN(s334ter) line 4 (abbreviated s334ter 4).
- s334ter 4 TgN(s334ter) line 4
- Expression of the mutated opsin transgene begins at postnatal day P5 in these rats, leading to a gradual death of photoreceptor cells.
- These rats develop an anatomically normal retina up to PI 5, with the exception of a slightly increased number of pyknotic photoreceptor nuclei in the outer nuclear layer (ONL) than in non-transgenic control rats.
- the rate of photoreceptor cell death is approximately linear until P60, resulting in loss of 40-60% of the photoreceptors.
- FIV ⁇ gal feline immunodeficiency virus expressing E. coli ⁇ -galactosidase
- FIV ⁇ gluc FIV expressing ⁇ -glucuronidase
- FIV packaging constructs were generated in several steps from the full-length FIV molecular clone, FIV-34TF10 (NIH AIDS Research and Reference Reagent Program, Cat. No. 1236; Phillips et al., J Virol. 66: 5464, 1992, Talbott et al., PNAS 86: 5743, 1989) as described above in Example IB.
- the FIV vector constructs were generated by insertion of an expression cassette into the pVET L FIV vector backbone (Johnston et al, J Virol 73:4991-5000, 1999).
- ⁇ -galactosidase expression was driven by the CMV promoter, while the ⁇ -glucuronidase expression was driven by the RSV promoter (Johnston et al., J Virol 73:4991-5000, 1999).
- the construction of VSV-g envelope expression plasmid, pCMV-G has been previously described (Yee et al., PNAS 97:9564-9568, 1994).
- the generation of psuedotyped FIV ⁇ gal and FIV ⁇ gluc vector particles through transient transfection has been described (Johnston et al., J Virol 73:4991- 5000, 1999).
- mice All animals used in this example were between 4 and 8 weeks old and weighed between 12 and 24 grams. Mice were anesthetized with Ketamine-Xylazine (ketamine, 100-125 mg/kg; xylazine, 10-12.5 mg/kg). Eyes were dilated with 0.2% cyclopentolate, 0.5% phenylephrine, and 0.05% tropicamide. After dilation a drop of 0.5% proparacaine was administered as a topical anesthetic. A microscalpel was used to make a small self closing incision in the cornea just central to the free border of the iris.
- FIG. 1 1 x 10 8 TU, Ad 1 x 10 10 IU
- saline saline
- injections were observed at low magnification with a stereo microscope.
- the incision was coated with antibiotic ointment to help prevent leakage and infection.
- the animals were injected with 1 milliliter normal saline subcutaneously and placed under a heat lamp.
- slides were fixed with an acetone- formalin solution, washed two times for 5 minutes with 0.05 M sodium acetate buffer, pH 4.5, and incubated in 0.25 mM Naph-As-Bi- ⁇ -glucuronidide (Sigma, St. Louis, MO) in 0.05 M sodium acetate buffer, pH 4.5, all at 4°C.
- the slides were then developed for 2 hours at 37°C with 0.25 mM Naph-As-Bi- ⁇ -glucuronidide in 0.05 M sodium acetate buffer, pH 5.2, with 1 :500 2% hexazotized pararosaliline (Sigma) (Bancroft, 1982; Roessler, 1994). Slides were subsequently dried and coverslipped with permount (Fisher).
- FIV ⁇ gal and AdeGFP were mixed and 2 ⁇ l injected intravitreally.
- FIV ⁇ gal and AdeGFP were mixed and 2 ⁇ l injected intravitreally.
- the rabbit polyclonal antibody was preabsorbed for 24 hours on naive mouse tissue. All antibodies were diluted in 3.0% BSA crystilline fraction (Sigma, St. Louis, MO) and 0.3% saponin (Sigma, St. Louis, MO) in PBS.
- mice were used for ⁇ -gal and eGFP injections due to the lack of pigmentation in the eye, therefore allowing the transgene product to be visualized easier.
- Eyes were evaluated at either 1 or 3 weeks after FIV ⁇ gal injection, ⁇ -galactosidase-positive cells were found predominantly in the retinal pigmented epithelium (RPE). Positive cells were also seen in the ciliary process, iris, and corneal endothelium. The distribution of positive cells did not vary over time.
- RPE retinal pigmented epithelium
- Treated MPS mouse eyes were examined for ⁇ -glucuronidase activity by histochemical stain as described above.
- the red precipitate reaction product may be obscured by the pigmentation in areas of the eye. Due to the secreted nature of ⁇ - glucuronidase positive staining cells were found throughout the eye at all time points (2, 7, and 12 weeks). These eyes were analyzed for the presence of distended lysosomes using electron microscopy.
- the three main cell types that were evaluated for distended lysosomal presence were the corneal endothelium, nonpigmented epithelium of the ciliary process, and the retinal pigmented epithelium.
- Buffer injected and non-treated eyes showed numerous large distended lysosomes within the cytoplasmic space in all of these cell types as well as other cell types throughout the eye. In the cases of the three aforementioned cell types, all appeared swollen and larger than the cells in age-matched control animals. In the case of the RPE the pigment granules were displaced to the apical surface. However, the neural retina remained relatively unaffected with very few cells containing notable distended lysosomes.
- ⁇ -glucuronidase enzyme levels were measured in different ocular tissues. At the time of sacrifice the fluid was removed from the eye and the cornea and retina were dissected out for analysis.
- Corneal endothelial cells and the nonpigmented epithelium of the ciliary process were sporadically infected and no positive keratocytes were found. Therefore correction of the phenotype in these cells is most likely attributable to the uptake of extracellular ⁇ -glucuronidase that has been secreted by transduced cells.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001500794A JP2003523174A (en) | 1999-05-28 | 2000-05-26 | Use of a recombinant gene delivery vector to treat or prevent a lysosomal storage disease |
CA002375123A CA2375123A1 (en) | 1999-05-28 | 2000-05-26 | Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders |
EP00937832A EP1183384A1 (en) | 1999-05-28 | 2000-05-26 | Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders |
AU52955/00A AU5295500A (en) | 1999-05-28 | 2000-05-26 | Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13652799P | 1999-05-28 | 1999-05-28 | |
US60/136,527 | 1999-05-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000073482A1 true WO2000073482A1 (en) | 2000-12-07 |
WO2000073482A9 WO2000073482A9 (en) | 2002-04-18 |
Family
ID=22473225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/014582 WO2000073482A1 (en) | 1999-05-28 | 2000-05-26 | Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1183384A1 (en) |
JP (1) | JP2003523174A (en) |
AU (1) | AU5295500A (en) |
CA (1) | CA2375123A1 (en) |
WO (1) | WO2000073482A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002049422A2 (en) * | 2000-12-20 | 2002-06-27 | K.U. Leuven Research And Development | Non-human animal disease models |
WO2002099092A2 (en) * | 2001-06-07 | 2002-12-12 | Hemebiotech A/S | Production of recombinant human lysosomal alpha-mannosidase |
WO2005094874A1 (en) * | 2004-04-01 | 2005-10-13 | Zymenex A/S | Medical use of alpha-mannosidase |
EP1818395A1 (en) | 2006-02-08 | 2007-08-15 | Diatos | Compositions and methods for treating lysosomal storage diseases |
CN110621774A (en) * | 2016-10-14 | 2019-12-27 | 儿童医疗中心有限公司 | Compositions and methods for treating central nervous system diseases and disorders |
US12000843B2 (en) | 2018-01-16 | 2024-06-04 | Children's Medical Center Corporation | Compositions and methods for diagnosing and treating peroxisomal diseases |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997032983A1 (en) * | 1996-03-05 | 1997-09-12 | The Regents Of The University Of California | Recombinant live feline immunodeficiency virus and proviral dna vaccines |
WO1998041644A1 (en) * | 1997-03-18 | 1998-09-24 | Introgene B.V. | Methods and compositions for genetically modifying primate bone marrow cells |
WO1999036511A2 (en) * | 1998-01-16 | 1999-07-22 | Chiron Corporation | Feline immunodeficiency virus gene therapy vectors |
-
2000
- 2000-05-26 JP JP2001500794A patent/JP2003523174A/en not_active Withdrawn
- 2000-05-26 EP EP00937832A patent/EP1183384A1/en not_active Withdrawn
- 2000-05-26 AU AU52955/00A patent/AU5295500A/en not_active Abandoned
- 2000-05-26 WO PCT/US2000/014582 patent/WO2000073482A1/en not_active Application Discontinuation
- 2000-05-26 CA CA002375123A patent/CA2375123A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997032983A1 (en) * | 1996-03-05 | 1997-09-12 | The Regents Of The University Of California | Recombinant live feline immunodeficiency virus and proviral dna vaccines |
WO1998041644A1 (en) * | 1997-03-18 | 1998-09-24 | Introgene B.V. | Methods and compositions for genetically modifying primate bone marrow cells |
WO1999036511A2 (en) * | 1998-01-16 | 1999-07-22 | Chiron Corporation | Feline immunodeficiency virus gene therapy vectors |
Non-Patent Citations (4)
Title |
---|
BOSCH A. ET AL.: "Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer.", HUMAN GENE THERAPY, vol. 11, no. 8, 20 May 2000 (2000-05-20), pages 1139 - 1150, XP000939360, ISSN: 1043-0342 * |
MIYOSHI H. ET AL.: "Development of self-inactivating lentivirus vector.", JOURNAL OF VIROLOGY, vol. 72, no. 10, - October 1998 (1998-10-01), pages 8150 - 8157, XP002147113 * |
MIYOSHI H. ET AL.: "Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 94, no. 19, 1997, 1997, pages 10319 - 10323, XP002147112, ISSN: 0027-8424 * |
NAFFAKH N. ET AL.: "GENE THERAPY FOR LYSOSOMAL DISORDERS", JOURNAL OF EXPERIMENTAL AND CLINICAL HEMATOLOGY / NOUVELLE REVUE FRANCAISE HEMATOLOGIE, vol. 36, no. SUPPL. 01, 1994, pages S11 - S16, XP000676893, ISSN: 0029-4810 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002049422A2 (en) * | 2000-12-20 | 2002-06-27 | K.U. Leuven Research And Development | Non-human animal disease models |
WO2002049422A3 (en) * | 2000-12-20 | 2002-11-14 | Leuven K U Res & Dev | Non-human animal disease models |
WO2002099092A2 (en) * | 2001-06-07 | 2002-12-12 | Hemebiotech A/S | Production of recombinant human lysosomal alpha-mannosidase |
WO2002099092A3 (en) * | 2001-06-07 | 2004-03-04 | Hemebiotech As | Production of recombinant human lysosomal alpha-mannosidase |
WO2005094874A1 (en) * | 2004-04-01 | 2005-10-13 | Zymenex A/S | Medical use of alpha-mannosidase |
EP1818395A1 (en) | 2006-02-08 | 2007-08-15 | Diatos | Compositions and methods for treating lysosomal storage diseases |
CN110621774A (en) * | 2016-10-14 | 2019-12-27 | 儿童医疗中心有限公司 | Compositions and methods for treating central nervous system diseases and disorders |
US11957713B2 (en) | 2016-10-14 | 2024-04-16 | Children's Medical Center Corporation | Compositions and methods for treating diseases and disorders of the central nervous system |
US12000843B2 (en) | 2018-01-16 | 2024-06-04 | Children's Medical Center Corporation | Compositions and methods for diagnosing and treating peroxisomal diseases |
Also Published As
Publication number | Publication date |
---|---|
EP1183384A1 (en) | 2002-03-06 |
WO2000073482A9 (en) | 2002-04-18 |
AU5295500A (en) | 2000-12-18 |
CA2375123A1 (en) | 2000-12-07 |
JP2003523174A (en) | 2003-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6730297B1 (en) | Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders | |
US20190127708A1 (en) | Messenger rna based viral production | |
US7592321B2 (en) | Methods of treating lysosomal storage related diseases by gene therapy | |
US20020037281A1 (en) | Methods of transducing neural cells using lentivirus vectors | |
US20100172871A1 (en) | Muller Cell Specific Gene Therapy | |
AU5694299A (en) | Adenoviruses deleted in the IVa2, 100K, polymerase and/or preterminal protein sequences | |
WO1997020935A2 (en) | Viral vectors | |
US20240050537A1 (en) | Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua) | |
US20230332112A1 (en) | Novel In Vitro and In Vivo Enrichment Strategy Targeting Lymphocytes Derived from Vector Transduced HSCS for Therapy of Disorders | |
JP2023052096A (en) | Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2 sulfatase (ids) produced by human neural or glial cells | |
EP1501465B1 (en) | Vectors having both isoforms of beta-hexosaminidase | |
US20210275647A1 (en) | Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua) | |
JP2005533485A (en) | Gene transfer system based on recombinant bovine immunodeficiency virus | |
Loewen et al. | Lentiviral vectors | |
EP1183384A1 (en) | Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders | |
Derksen et al. | Feline immunodeficiency virus vectors. Gene transfer to mouse retina following intravitreal injection | |
Enomaa et al. | Correction of deficient enzyme activity in a lysosomal storage disease, aspartylglucosaminuria, by enzyme replacement and retroviral gene transfer | |
Villani et al. | Correction of mucopolysaccharidosis type IIIb fibroblasts by lentiviral vector-mediated gene transfer | |
Occhiodoro et al. | Correction of α-L-fucosidase deficiency in fucosidosis fibroblasts by retroviral vector-mediated gene transfer | |
JP2006502240A (en) | Vector system | |
WO2024010067A1 (en) | Nuecleic acid molecule, vector, recombinant cells, and drug for treating central nervous system diseases | |
DE69829174T2 (en) | EXPRESSION OF A MODIFIED "FOAMY VIRUS ENVELOPE PROTEIN" (SLEEP PROTEIN) | |
CA3218213A1 (en) | Gene therapy constructs and methods for treatment of hearing loss |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2375123 Country of ref document: CA Ref country code: CA Ref document number: 2375123 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 500794 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000937832 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000937832 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/5-5/5, DRAWINGS, REPLACED BY NEW PAGES 1/5-5/5; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000937832 Country of ref document: EP |